FASCINATION ABOUT TYROSINASE-IN-12

MI-CP151 was a period 1b randomised, double-blind, placebo managed, dose-escalation, multicentre research To guage numerous intravenous doses of sifalimumab, in Grownup patients with dermatomyositis or polymyositis (NCT00533091). Most important trial objectives ended up to evaluate the protection and tolerability of sifalimumab in dermatomyositis o